? BIOSPECIMEN SERVICES SHARED RESOURCE (BSSR) The mission of the BSSR is to support innovative translational research to advance the prevention, diagnosis, and treatment of cancer through the provision of biospecimens and clinical data.
The Specific Aims are to: 1) collect data and specimens from OSUCCC cancer patients using the IRB-approved Total Cancer Care (TCC) universal consenting and biobanking protocol for future unspecified research; 2) prospectively procure biospecimens for specific IRB-approved protocols; and 3) provide high quality, centralized biorepository services for IRB-approved, grant-funded and large institutional projects in a CAP-accredited biorepository. Over the current grant cycle, the major changes for the BSSR include: a) implementation of TCC across all Disease Specific Research Groups (DSRGs) covering all cancers - TCC now includes 57,256 consented subjects resulting in regular usage of biospecimens and data; and, b) the ORIEN AVATAR program was initiated, providing OSUCCC members with research grade next generation exome sequencing results on tumor and normal tissue with clinical annotation from 3,049 TCC subjects at OSU and 11,500 across ORIEN (the OSUCCC is a major contributor of samples). During the current grant cycle, the BSSR provided key services in support of 122 publications (35 > 10 impact factor), 105 users, and 24 NCI grants, including 1 K01, 1 K12, 2 P01s, 2 P50s, 11 R01s, 4 R21s, 1 U10, 1 UH2, and 1 UM1. Over the next grant cycle, BSSR will contribute to each of the new strategic priorities for the OSUCCC by providing biospecimens and high quality genomic and clinical data as requested by immuno-oncology, translational genomics, cancer engineering and cancer prevention and survivorship investigators. Each area will be supported by the TCC, and given the robust faculty recruitment and regularly increasing patient volumes; there will be an increase in prospective procurement and biobanking as well. Given the robust OSUCCC recruitment and increasing patient volumes, demand for services and new technologies will increase. The BBSR will expand its staff, instrumentation and services before capacity is reached. The annual budget of the BSSR is $2,206,277, yet the CCSG request is $179,168. As such, The BSSR leverages extensive institutional support and seeks only 8.1% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090005
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E et al. (2018) Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res 4:26-38

Showing the most recent 10 out of 2602 publications